Zobrazeno 1 - 10
of 585
pro vyhledávání: '"trifluridine-tipiracil"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Trifluridine/tipiracil (FTD/TPI) with or without bevacizumab is an effective treatment for metastatic colorectal cancer (mCRC). As this agent is mainly excreted via the kidney, we aimed to evaluate the impact of renal impairment (RI) on the
Externí odkaz:
https://doaj.org/article/aadfc24014774c979c95a472172d6834
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
BackgroundThe combination of trifluridine/tipiracil (FTD/TPI) and bevacizumab has demonstrated promising efficacy and safety in the treatment of colorectal cancer (CRC). This study aims to evaluate the cost-effectiveness of trifluridine/tipiracil com
Externí odkaz:
https://doaj.org/article/ea5f15b519cb477097f9330981491ed9
Autor:
T. Sakakida, T. Masuishi, M. Asayama, S. Mitani, A. Makiyama, T. Shimura, H. Takeda, Y. Suwa, Y. Takano, K. Sawada, T. Yomoda, H. Mushiake, Y. Okumura, M. Yokota, M. Yamamoto, Y. Kito, K. Ogawa, H. Matsuoka, M. Ando, M. Tajika, K. Muro, C. Kudo, A. Mishima, K. Murotani, H. Taniguchi
Publikováno v:
ESMO Gastrointestinal Oncology, Vol 5, Iss , Pp 100090- (2024)
Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) is the established therapy for refractory metastatic colorectal cancer, but there are concerns regarding the regimen’s complexity and hematotoxic effects, especially for patients with organ dy
Externí odkaz:
https://doaj.org/article/586ad71aa6704810b01a6527c3af0d51
Autor:
Bülent Karabulut, Burcu Çakar
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 630-639 (2024)
Introduction: Although long-term survival in patients with metastatic colorectal cancer (mCRC) is limited, treatments for third-line and later treatment are now recommended. We describe a patient who achieved long-term survival when they received thi
Externí odkaz:
https://doaj.org/article/cab300c40ec24dde8134b77559ec4501
Autor:
Yukiya Narita, Takatsugu Ogata, Yasunobu Ishizuka, Tomoki Sakakida, Munehiro Wakabayashi, Hiroyuki Kodama, Kazunori Honda, Toshiki Masuishi, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Masahiro Tajika, Kei Muro
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The combination of trifluridine/tipiracil hydrochloride (FTD/TPI) plus ramucirumab has demonstrated clinical activity in patients with advanced gastric cancer (AGC). We evaluated the efficacy and safety of this combination compared with thos
Externí odkaz:
https://doaj.org/article/4d7761430fc7499a8389396db24e579c
Autor:
Francisco Cezar Aquino de Moraes, Felipe Dircêu Dantas Leite Pessôa, Caio Henrique Duarte de Castro Ribeiro, Marianne Rodrigues Fernandes, Rommel Mario Rodríguez Burbano, Ney Pereira Carneiro dos Santos
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Colorectal cancer is the leading cause of cancer death worldwide. The first and second lines of treatment for metastatic colorectal cancer (mCRC) include chemotherapy based on 5-fluorouracil. However, treatment following progression on the f
Externí odkaz:
https://doaj.org/article/12a09e4373004ed5af540e711ea7a983
Autor:
Yongli Hu, Yan Du, Zhisheng Qiu, Chenglou Zhu, Junhong Wang, Tong Liang, Tianxiang Liu, Mingxu Da
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveThe objective of this research is to scrutinize adverse events (AEs) linked to Trifluridine/Tipiracil (TFTD/TPI), using data from the FDA Adverse Event Reporting System (FAERS) database.MethodsThe AEs data related to TFTD/TPI were collected
Externí odkaz:
https://doaj.org/article/1d537b76a5b54d4ca78d22adfbd9f820
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Colorectal cancer ranks second in cancer-related deaths throughout the world. At the time of diagnosis, at least 20% of the patients with CRC had already developed metastases. Treating and effectively managing metastatic colorectal cancer remains an
Externí odkaz:
https://doaj.org/article/b9582c9a9a42458bb742eaf50e7f8905
Autor:
Daichi Watanabe, Hironori Fujii, Koichi Ohata, Hirotoshi Iihara, Akitaka Makiyama, Ryo Kobayashi, Chiemi Hirose, Shiori Hishida, Serika Matsuoka, Jesse Yu Tajima, Shigeru Kiyama, Takao Takahashi, Akio Suzuki, Nobuhisa Matsuhashi
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Several studies have reported an association between severe neutropenia and long-term survival in patients treated with trifluridine-tipiracil (TAS-102). Because some of these studies failed to address immortality time bias, howev
Externí odkaz:
https://doaj.org/article/cb8ce677d92a4090b254e842a7afaacd
Autor:
Naoki Takahashi, Hiroki Hara, Kengo Nagashima, Kenro Hirata, Toshiki Masuishi, Toshihiko Matsumoto, Hisato Kawakami, Kentaro Yamazaki, Shuichi Hironaka, Narikazu Boku, Kei Muro
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Trifluridine/tipiracil (FTD/TPI) prolongs survival in the third- or later-line treatment for advanced gastric cancer (GC), esophagogastric junction (EGJ) adenocarcinoma, and colorectal cancer. While single-arm phase II trials show
Externí odkaz:
https://doaj.org/article/7e4e091163904bb1a0330ed3bafd6354